Tarceva
-
Roche and OSI Pharmaceuticals Gain Approval for Cancer Treatment
Roche and OSI Pharmaceuticals have gained US Food and Drug Administration (FDA) approval for the use of Tarceva as a maintenance treatment for non-small cell lung cancer. The FDA's decision comes despite an earlier negative opinion from its advis…
Tarceva | 26 May 2010
